Literature DB >> 3354997

Upper airway muscle activation is augmented in patients with obstructive sleep apnea compared with that in normal subjects.

P M Suratt1, R F McTier, S C Wilhoit.   

Abstract

Although phasic electromyographic (EMG) activity of upper airway muscles in patients with obstructive sleep apnea (OSA) decreases at apnea onset, the presence of phasic activity in normal subjects has not been studied and compared with that in patients. We consequently compared the percentage of total sleep time in which phasic activity of the genioglossal EMG activity was present in 8 adult patients with OSA and 3 control groups without OSA, one consisting of 6 young, normal subjects, one matched for age, and one matched for age and obesity. From wakefulness to sleep, genioglossal EMG phasic activity time increased in patients but not in control subjects. Patients with OSA had more phasic genioglossal group EMG activity during non-REM sleep than did control subjects. At apnea onset, phasic EMG activity decreased in patients but remained greater than zero. In many control subjects, phasic activity was not detected, yet their pharyngeal airway remained patent. We conclude that phasic genioglossal group EMG activity occurs more frequently during sleep in patients with OSA than in control subjects, suggesting that it is a compensatory mechanism that occurs when patency of the pharyngeal airway is precarious.

Entities:  

Mesh:

Year:  1988        PMID: 3354997     DOI: 10.1164/ajrccm/137.4.889

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  42 in total

1.  Mortised genioplasty in the treatment of obstructive sleep apnea: an historical perspective and modification of design.

Authors:  B Hendler; K Silverstein; H Giannakopoulos; B J Costello
Journal:  Sleep Breath       Date:  2001-12       Impact factor: 2.816

2.  Differential expression of lipid and carbohydrate metabolism genes in upper airway versus diaphragm muscle.

Authors:  Erik van Lunteren; Sarah Spiegler; Michelle Moyer
Journal:  Sleep       Date:  2010-03       Impact factor: 5.849

3.  Waking genioglossal electromyogram in sleep apnea patients versus normal controls (a neuromuscular compensatory mechanism).

Authors:  W S Mezzanotte; D J Tangel; D P White
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

4.  Catecholaminergic A1/C1 neurons contribute to the maintenance of upper airway muscle tone but may not participate in NREM sleep-related depression of these muscles.

Authors:  Irma Rukhadze; Nancy J Carballo; Sathyajit S Bandaru; Atul Malhotra; Patrick M Fuller; Victor B Fenik
Journal:  Respir Physiol Neurobiol       Date:  2017-07-12       Impact factor: 1.931

5.  Neural drive to human genioglossus in obstructive sleep apnoea.

Authors:  Julian P Saboisky; Jane E Butler; David K McKenzie; Robert B Gorman; John A Trinder; David P White; Simon C Gandevia
Journal:  J Physiol       Date:  2007-10-04       Impact factor: 5.182

6.  Rats subjected to chronic-intermittent hypoxia have increased density of noradrenergic terminals in the trigeminal sensory and motor nuclei.

Authors:  Pari Mody; Irma Rukhadze; Leszek Kubin
Journal:  Neurosci Lett       Date:  2011-10-13       Impact factor: 3.046

7.  Effect of chronic intermittent hypoxia on noradrenergic activation of hypoglossal motoneurons.

Authors:  Georg M Stettner; Victor B Fenik; Leszek Kubin
Journal:  J Appl Physiol (1985)       Date:  2011-10-20

8.  Hypoglossal premotor neurons of the intermediate medullary reticular region express cholinergic markers.

Authors:  Denys V Volgin; Irma Rukhadze; Leszek Kubin
Journal:  J Appl Physiol (1985)       Date:  2008-09-04

Review 9.  Flow-regulatory function of upper airway in health and disease: a unified pathogenetic view of sleep-disordered breathing.

Authors:  S S Park
Journal:  Lung       Date:  1993       Impact factor: 2.584

Review 10.  Pathophysiology of sleep apnea.

Authors:  Jerome A Dempsey; Sigrid C Veasey; Barbara J Morgan; Christopher P O'Donnell
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.